Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划 项目摘要/摘要 达纳·法伯/哈佛癌症联盟临床肿瘤学职业发展计划的目标 (DF/HCC K12)是为下一代肿瘤学临床研究人员做准备，以便在 实验室科学、临床医学和人口科学。DF/HCCK12于2002年首次获得资金， 资助了32位学者。受资助的学者基金非常成功，产出了215 过去10年毕业的学者出版物和46笔补助金，以及所有学者进步到 在工业或学术岗位上从事独立研究。我们提出了以下具体目标 续订K12以继续培训来自不同学科的医生/科学家： 目标1：我们将招募和挑选不同的K12学者群体。我们将每年发布一份申请， 应用程序(RFA)使用各种机制来接触尽可能广泛的应聘者。我们会 积极促进妇女和其他传统上在医学界任职人数不足的群体的参与。 内部咨询委员会(IAC)，由16名担任领导职务的DF/CC教职员工和 在原创研究和指导方面建立了跟踪记录，将与学者一起协助项目领导 选择。我们要求继续支持每年五名奖学金获得者，任期为两年， 再延长一年的可能性取决于取得的足够进展和继续证明有必要 有指导的支持。 目标2：我们将提供严格的教学培训、职业发展和辅导计划 临床肿瘤学研究。每名学者将由两名教师指导，一名负责实验室(或数据) 科学)培训，一个用于临床研究。由35名高素质和上进心的教师组成的团队 已经确定了导师，但学者们可能会选择从1100人中选择更多的导师 七个DF/HCC机构的调查人员，以及麻省理工学院科赫研究所和 哈佛大学和麻省理工学院博德学院。将制定个性化的职业发展计划，包括 必备和可选教学培训的组成部分，动手实验室研究，以及开发 临床试验。包括了侧重于多样性、公平和包容性的具体所需培训。 目标3：我们将监控绩效并细化K12计划，以优化招聘和 培训临床肿瘤学研究方面的新研究员。咨询委员会将审查年度进度报告 来自学者和导师的建议，并就指导和/或研究重点的变化提出建议，如 需要的。外部咨询委员会(EAC)，由来自其他成功的K12计划的五个PD组成， 将评估计划绩效，参加年度务虚会，并为计划提供建议 对K12领导层的增强。该计划将跟踪学者的工作效率，包括演讲、 每年出版、推广、资助和临床试验活动。

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology Project Summary/Abstract The goal of the Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology (DF/HCC K12) is to prepare the next generation of clinical investigators in oncology to work at the interface of laboratory science, clinical medicine, and population science. The DF/HCC K12 was first funded in 2002 and has supported 32 Scholars. The funded Scholars have been exceptionally successful, with an output of 215 publications and 46 grants for Scholars graduating in the past 10 years, and all Scholars progressing to independent research careers in industry or academic positions. We propose the following Specific Aims for the renewal of this K12 to continue training physician/scientists from diverse disciplines: Aim 1: We will recruit and select a diverse group of K12 Scholars. We will issue an annual Request for Applications (RFA) using a variety of mechanisms to reach the widest possible pool of candidates. We will aggressively promote the participation of women and other groups traditionally under-represented in medicine. An Internal Advisory Committee (IAC), comprised of 16 DF/HCC faculty members with leadership roles and established track records in original research and mentoring, will assist Program Leadership with Scholar selection. We request a continuation of support for five Scholars per year with two-year appointments and the potential for one additional year contingent on sufficient progress and continued demonstration of a need for mentored support. Aim 2: We will provide a program of rigorous didactic training, career development, and mentored clinical oncology research. Each Scholar will be guided by two Faculty Mentors, one for laboratory (or data science) training, and one for clinical investigation. A group of 35 highly qualified and motivated Faculty Mentors have been identified, but Scholars may elect to include additional mentors from the pool of >1,100 investigators within the seven DF/HCC institutions, as well as faculty from the Koch Institute at MIT and the Broad Institute of Harvard and MIT. An individualized career development plan will be devised that includes components of required and optional didactic training, hands-on laboratory research, and development of a clinical trial. Specific required training has been included that focuses on Diversity, Equity, and Inclusion. Aim 3: We will monitor the performance and refine the K12 Program to optimize recruitment and training of new investigators in clinical oncology research. The IAC will review annual progress reports from Scholars and Mentors and make recommendations for changes in mentoring and/or research focus, as needed. An External Advisory Committee (EAC), comprised of five PDs from other successful K12 Programs, will evaluate Program performance, participate in an annual retreat, and provide recommendations for Program enhancements to the K12 Leadership. The Program will track Scholar productivity, including presentations, publications, promotions, grants, and clinical trial activity on an annual basis.